Neurogene (NGNE) Invested Capital (2013 - 2014)

Neurogene (NGNE) has 8 years of Invested Capital data on file, last reported at $19000.0 in Q4 2025.

• Quarterly Invested Capital fell 76.25% year-over-year to $19000.0 in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $19000.0 (down 93.17% YoY) and the FY2025 annual result came in at $19000.0, down 76.25% from the prior year.
• Invested Capital declined to $19000.0 in Q4 2025, from $80000.0 in the prior quarter.
• In the past five years, Invested Capital ranged from a high of $122000.0 in Q4 2021 to a low of $19000.0 in Q4 2025.
• A 5-year average of $89000.0 and a median of $94500.0 in 2024 frame the typical range for Invested Capital.
• Annual changes were most pronounced in 2023 — Invested Capital rose 18.89% — and 2025, when it tumbled 76.25%.
• Tracing NGNE's Invested Capital over 5 years: stood at $122000.0 in 2021, then fell by 26.23% to $90000.0 in 2022, then climbed by 18.89% to $107000.0 in 2023, then declined by 25.23% to $80000.0 in 2024, then plunged by 76.25% to $19000.0 in 2025.
• The last three Invested Capital figures came in at $19000.0 (Q4 2025), $80000.0 (Q4 2024), and $93000.0 (Q3 2024), per Business Quant data.